

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10587819
	Filing Date		2007-07-28
	First Named Inventor	Anil CHAUHAN	
	Art Unit	1644	
	Examiner Name	TBA	Sharon Wen
	Attorney Docket Number		60020200-0011

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	WO 03/012396	WO		2003-02-13	Chauhan		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10587819
Filing Date	2007-07-28
First Named Inventor	Anil CHAUHAN
Art Unit	1644
Examiner Name	TBA
Attorney Docket Number	60020200-0011

1	CHAUHAN et al., Membrane attack complexes (MAC) in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), Arthritis Rheum, 2004, p. S518, abstract	<input type="checkbox"/>
2	LARSSON et al., Binding of complement component C5 to model immune complexes and the use of anti-C5 antibodies for determination of C50containing circulating immune complexes, Journal of Clinical and Laboratory Immunology, 1989, p. 5-9, vol. 28.	<input type="checkbox"/>
3	GARRED et al., C3, C4 and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes, Journal of Immunology, 1990, p. 198-203, vol. 144.	<input type="checkbox"/>
4	CHAUHAN et al., Role of complement components in defining the beneficial effects of plasma exchange in organ transplantation, Human Immunology, 2003, p. S27, abstract.	<input type="checkbox"/>
5	NYDEGGER et al., Current precision of immunological extracorporeal plasma treatment, Transfusion and Apheresis Science, 2001, p. 39-47, vol. 24.	<input type="checkbox"/>
6	SNYDER et al., Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma, Cancer, 1993, p. 1882-1892, vol. 71.	<input type="checkbox"/>
7	SASSO et al., Immunoglobulin binding properties of the Prosorba immunoadsorption column in treatment of rheumatoid arthritis, Therapeutic Apheresis and Dialysis, 2001, p. 84-91, vol. 5	<input type="checkbox"/>
8	European Search Report issued for related application PCT/US05/002586 dated 10 April 2008	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Sharon Wen/	Date Considered	02/24/2011
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.